Takeda beats Bristol Myers in psoriasis trial, showing 2.5x better clearance

Takeda’s experimental oral drug zasocitinib outperformed Bristol Myers Squibb’s approved therapy, Sotyktu, in a late-stage head-to-head trial.

Over 35% of patients using zasocitinib achieved complete skin clearance (PASI 100) after 16 weeks. This clearance rate exceeded Sotyktu’s performance by more than 2.5 times.

Zasocitinib met all key secondary endpoints and showed superior results as early as eight weeks.

Takeda plans to file for regulatory approval following these results. The drug poses a significant competitive challenge to Sotyktu in the oral psoriasis market.